Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

146.36 -2.40 (-1.61%)
Streaming Delayed Price Updated: 1:04 PM EST, Jan 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
49 50 Next >
Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Up Today?
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever. 
Via InvestorPlace
Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers
Via Benzinga
Why Is AST SpaceMobile (ASTS) Moving Today?
AST SpaceMobile (ASTS) stock is a hot topic on Monday as investors react to the company setting up its BlueWalker 3 satellite array. 
Via InvestorPlace
Why Is Biogen (BIIB) Stock Up Today?
Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial. 
Via InvestorPlace
Elliott Wave Technical Analysis: Biogen Inc. - Thursday, Nov. 10
Looking for a clear three-wave move pullback before considering any long-term longs. 
Via Talk Markets
Is Biogen Poised for a Bull Run?
Biogen has been a market-beating stock this year, but can that trend continue? 
Via The Motley Fool
Biogen (BIIB) Q3 2022 Earnings Call Transcript
BIIB earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Biogen Raises Annual Guidance Despite Q3 Earning Impacted By Biosimilar Competition
Via Benzinga
What's Going On With Biogen Stock Today?
Biogen Inc (NASDAQ: BIIB) shares are trading higher Monday after competitor Roche's Alzheimer's candidate did not meet its primary endpoint in recent studies. 
Via Benzinga
Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others
Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map. 
Via Investor's Business Daily
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark... 
Via Benzinga
Why Shares Of Eli Lilly And Biogen Are Rallying Today
Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday despite the negative broader market sentiment. 
Via Benzinga
Earnings Scheduled For October 25, 2022
Companies Reporting Before The Bell • UBS Gr (NYSE:UBS) is expected to report earnings for its third quarter. • SAP (NYSE:SAP) is expected to report earnings for its third quarter. 
Via Benzinga
Why Are Healthcare Stocks Down Today?
Healthcare stocks are falling after a false tweet from a Twitter account impersonating Eli Lilly. Here's what this news means for investors. 
Via InvestorPlace
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
Biogen Names Christopher Viehbacher President and Chief Executive Officer
Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies 
From Biogen Inc.
Via GlobeNewswire
The Power of McKinsey
Author Michael Forsythe talks about his new book, "When McKinsey Comes to Town: The Hidden Influence of the World's Most Powerful Consulting Firm." 
Via The Motley Fool
Biogen To Rally Around 15%? Here Are 5 Other Price Target Changes For Tuesday
Mizuho raised Biogen Inc. (NASDAQ: BIIB) price target from $270 to $325. Mizuho analyst Salim Syed maintained the stock with a Buy rating. Biogen shares fell 0.3% to close at $283.44 on Monday. 
Via Benzinga
Don't Get Used to Lower Medicare Part B Premiums -- Here's Why
Medicare might have to begin paying billions of extra dollars for new drugs in the not-too-distant future. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Stock Market Rally Resilient As Apple Bucks Megacap Meltdown: Weekly Review
The Dow and S&P 500 moved above a key level while the Nasdaq rose. 
Via Investor's Business Daily
Is Biogen Stock a Buy Now That Guidance Has Been Raised?
Biogen stock (NASDAQ:BIIB) continues to get excellent news. On Tuesday, the pharmaceutical company released its third-quarter results, and for the first time in a long time, investors found something... 
Via PressReach
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
Upgrades 
Via Benzinga
Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
From Biogen Inc.
Via GlobeNewswire
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS
From Biogen Inc.
Via GlobeNewswire
Is Biogen a Buy After It Boosted Guidance?
There's a much bigger story for this biotech than its improved 2022 outlook. 
Via The Motley Fool
Biogen Inc. Surpasses Q3 Earnings And Revenue Estimates
Biogen Inc. came out with quarterly earnings of $4.77 per share. 
Via Talk Markets
Biogen Inches Higher On Third-Quarter Beat, But All Eyes Watch Alzheimer's Drug
Biogen's partner, Eisai, will present Phase 3 results for lecanemab next month. 
Via Investor's Business Daily
Recap: Biogen Q3 Earnings
Biogen (NASDAQ:BIIB) reported its Q3 earnings results on Tuesday, October 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Biogen beat estimated earnings by... 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.